0
Editorial |

Emerging Infectious Diseases: Title and subTitle BreakA Clear and Present Danger to Humanity

Anthony S. Fauci, MD
[+] Author Affiliations

Author Affiliations: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

More Author Information
JAMA. 2004;292(15):1887-1888. doi:10.1001/jama.292.15.1887
Text Size: A A A
Published online

Extraordinary strides in identifying and eliminating the pathogens behind many of the major scourges of the last century prompted the US Surgeon General in 1967 to declare that the war against infectious diseases had been won.1 But the announcement was premature. The steady stream of emerging and reemerging infectious diseases since the 1960s has been a sobering wake-up call. Despite many accomplishments in the realm of antibiotics and vaccines, such a declaration of victory was not justified. It is now clearer than ever that the human species is in the midst of a war with the microbial world—a resilient foe that will never be completely defeated.2 - 4

The AIDS pandemic illustrates how a new human pathogen emerged as a result of a complex series of opportunities that were presented to an unusual virus that first infected primates.5 After the virus crossed over to humans, most likely as a result of genetic mutations together with accidental transmission, human immunodeficiency virus (HIV) rapidly spread among different population groups due to profound changes in social and economic conditions in certain countries.6

Today, public health officials are closely monitoring a massive outbreak of avian influenza in chickens that emerged in January 2004 in Southeast Asia.7 Ominously, the H5N1 strain of influenza virus involved in the epidemic crossed over to humans, resulting in at least 24 human deaths. In July 2004, the disease reemerged. At least 6 additional individuals in Vietnam and Thailand have died, and more suspicious deaths are under investigation.7 Public health officials are fearful that the avian form of the virus will acquire the genes of human influenza, allowing it to spread from person to person, potentially sparking a global outbreak to rival the 1918 influenza pandemic that killed 20 to 50 million individuals worldwide.8

The United States is now witnessing another wave of West Nile virus infections.9 In 1999, the disease first appeared in humans in eastern states, but now West Nile virus infection is seen throughout the country. This year, more western states, particularly Arizona and California, have been hit hard with more than 860 cases and 20 deaths reported through September 2004 in those 2 states alone.9

To add to these naturally occurring diseases, the threat of infectious agents that are deliberately introduced remains a major concern.10 The post–September 11 anthrax attacks alerted the world community to its vulnerability to potential acts of bioterrorism in which a host of deadly pathogens, including anthrax, smallpox, tularemia, botulism toxin, Ebola, and other lethal microbes could be unleashed at any time.

As frightening as this may seem, there is cause for some cautious optimism. Fortunately, clinicians now have an ever-growing toolbox of sophisticated technologies and strategies at their disposal. These will help detect, prevent, treat, and respond to new and old infectious agents as they emerge, whether by an act of nature or by deliberate design.1 - 2 ,4 The challenge is to put these tools to good use by vigilantly tracking and responding to potential outbreaks and epidemics as they arise, and by rapidly developing new technologies and strategies to help in the detection, prevention, treatment, and containment of new infections. Moreover, powerful new tools, including ones that expose the genetic signature of microbes, are being used to detect and identify known and novel pathogens and to develop new drugs and vaccines.1 - 2

New approaches for drug discovery and development have led to the availability of more than 20 anti-HIV medications that have greatly reduced AIDS mortality and extended the healthy life spans of those living with the disease.11 Scores of vaccine candidates are now in the pipeline to prevent infection by emerging microbes such as HIV, Ebola, West Nile virus, dengue virus, H5N1 avian influenza virus, and the virus that causes severe acute respiratory syndrome (SARS). The first new tuberculosis vaccines in 60 years recently entered clinical trials, and vaccines against the most menacing bioterrorist threats are being developed.2

At the same time, sophisticated satellites, geographic imaging systems, and information technology are helping researchers track changes in climate, vegetation, and water reservoirs. These technologies will monitor other environmental changes that might lead to new ecological niches that could promote emerging infections.2

In the ongoing war against these formidable microbial foes, there is no room for complacency, but rather it is critically important to remain ever-vigilant, poised to recognize and contain both old foes and new enemies. It is essential to continue to monitor factors that might lead to disease outbreaks, and to concurrently support the development of new technologies that help detect, prevent, and treat new and reemerging diseases.1 - 4

Microbial foes have the advantage of an extraordinary capacity to rapidly reproduce and adapt, thereby propagating themselves even in the face of impressive advances in public health and the availability of countermeasures such as diagnostics, therapeutics, and vaccines.12 This inherent adaptability of microbes can only be matched with the continual application of wit and technological capability.

The best defense for the human species against elimination by the ever-evolving waves of microbial pathogens are public health measures coordinated with biomedical research that will continue to provide innovative tools to counterbalance these endless microbial challenges.1 - 4 ,12 Ultimately, if medical science continues to fight these microbial foes to a draw, as has occurred for much of the past century, humanity will have won.

AUTHOR INFORMATION

Corresponding Author: Anthony S. Fauci, MD, NIAID/National Institutes of Health, Bldg 31, Room 7A03, MSC 2520, Bethesda, MD 20892-2520 (afauci@niaid.nih.gov).

Fauci AS. Infectious diseases: considerations for the 21st century.  Clin Infect Dis. 2001;32675-685
PubMed
Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases.  Nature. 2004;430242-249
PubMed
Krause RM. The Restless Tide: The Persistent Challenge of the Microbial World Washington, DC: National Foundation for Infectious Diseases; 1981
 Committee on Emerging Microbial Threats to Health in the 21st Century. Microbial Threats to Health in the United States: Emergence, Detection and Response. Smolinski MS, Hamburg MA, Lederberg J, eds. Washington, DC: National Academy Press; 2003
Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications.  Science. 2000;287607-614
PubMed
Quinn TC, Fauci AS. The AIDS epidemic: demographic aspects, population biology, and virus evolution. In: Krause RM, ed. Emerging Infections. New York, NY: Academic Press; 1998:327-363
World Health Organization.  Situation updates - Avian influenza. Available at: http://www.who.int/csr/disease/avian_influenza/updates/en/. Accessed September 28, 2004
Webby RJ, Webster RG. Are we ready for pandemic influenza?  Science. 2003;3021519-1522
PubMed
Centers for Disease Control and Prevention.  West Nile Virus Activity in the United States. 2004 Available at: http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount04_detailed.htm. Accessed September 25, 2004
Lane HC, Fauci AS. Bioterrorism on the home front: a new challenge for American medicine.  JAMA. 2001;2862595-2597
PubMed
Joint United Nations Programme on HIV/AIDS.  2004 Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2004
Lederberg J. Infectious history.  Science. 2000;288287-293
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Fauci AS. Infectious diseases: considerations for the 21st century.  Clin Infect Dis. 2001;32675-685
PubMed
Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases.  Nature. 2004;430242-249
PubMed
Krause RM. The Restless Tide: The Persistent Challenge of the Microbial World Washington, DC: National Foundation for Infectious Diseases; 1981
 Committee on Emerging Microbial Threats to Health in the 21st Century. Microbial Threats to Health in the United States: Emergence, Detection and Response. Smolinski MS, Hamburg MA, Lederberg J, eds. Washington, DC: National Academy Press; 2003
Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications.  Science. 2000;287607-614
PubMed
Quinn TC, Fauci AS. The AIDS epidemic: demographic aspects, population biology, and virus evolution. In: Krause RM, ed. Emerging Infections. New York, NY: Academic Press; 1998:327-363
World Health Organization.  Situation updates - Avian influenza. Available at: http://www.who.int/csr/disease/avian_influenza/updates/en/. Accessed September 28, 2004
Webby RJ, Webster RG. Are we ready for pandemic influenza?  Science. 2003;3021519-1522
PubMed
Centers for Disease Control and Prevention.  West Nile Virus Activity in the United States. 2004 Available at: http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount04_detailed.htm. Accessed September 25, 2004
Lane HC, Fauci AS. Bioterrorism on the home front: a new challenge for American medicine.  JAMA. 2001;2862595-2597
PubMed
Joint United Nations Programme on HIV/AIDS.  2004 Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2004
Lederberg J. Infectious history.  Science. 2000;288287-293
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles